ABSTRACT
Rosacea is a chronic inflammatory disorder of the central face with multiple overlapping presentations. Recent advancements are reshaping our understanding of rosacea from both a pathophysiologic perspective and clinical approach to therapy, introducing novel agents that have improved patient outcomes and reduced morbidity. In this article, we aim to outline the advancements in understanding, diagnosing, and managing rosacea and to familiarize physicians with the literature, thereby allowing us to better practice safe and effective medicine.
Subject(s)
Holistic Health , Rosacea , Humans , Rosacea/diagnosis , Rosacea/etiology , Rosacea/therapyABSTRACT
Although patients with rosacea often consult dermatologists for dietary factors that might be related to their skin disorders, few studies have been conducted to research the relationship between rosacea and dietary factors. The purpose of this study was to evaluate the potential relationship between rosacea and diet among the large Chinese population with rosacea, which would provide dietary guidelines for patients with rosacea. A multicenter case-control study was conducted. The feeding frequency 2 years before the occurrence of rosacea was collected by standardized questionnaires. Multiple logistic regression analysis was used to calculate risks related to the diet. One thousand three hundred and forty-seven patients with rosacea and 1290 controls were enrolled in our study. We found that high-frequency intake of fatty food and tea presented a positive correlation with rosacea, while high-frequency dairy product intake showed significant negative correlation with rosacea. Sweet food, coffee and spicy food appeared to be independent of any subset of rosacea in our study. However, high-frequency dairy product intake showed a borderline beneficial effect on rosacea severity. We further analyzed the correlation between diet and the subtype of rosacea. We found that high-frequency fatty intake was associated with erythematotelangiectatic rosacea (ETR) and phymatous rosacea, while high-frequency tea intake was only associated with ETR. In addition, high-frequency dairy product intake showed negative correlations with ETR and papulopustular rosacea. Rosacea is associated with some dietary factors, and our study is valuable in establishing dietary guidelines to prevent and improve rosacea.
Subject(s)
Feeding Behavior/physiology , Rosacea/etiology , Adolescent , Adult , Case-Control Studies , China , Dairy Products , Dietary Fats/adverse effects , Female , Humans , Male , Middle Aged , Retrospective Studies , Rosacea/diagnosis , Rosacea/prevention & control , Severity of Illness Index , Tea/adverse effects , Young AdultABSTRACT
Granulomatous rosacea and periorificial dermatitis are common skin conditions affecting the face. This article examines the historical origin, causes, clinical presentation, and management strategies for these entities.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Dermatitis, Perioral/therapy , Dermatologic Agents/therapeutic use , Lasers, Dye/therapeutic use , Photochemotherapy , Rosacea/therapy , Skin/pathology , Adrenal Cortex Hormones/adverse effects , Benzoyl Peroxide/therapeutic use , Dermatitis, Perioral/diagnosis , Dermatitis, Perioral/etiology , Dicarboxylic Acids/therapeutic use , Facial Dermatoses/diagnosis , Facial Dermatoses/etiology , Facial Dermatoses/therapy , Humans , Low-Level Light Therapy , Metronidazole/therapeutic use , Rosacea/diagnosis , Rosacea/etiology , Toothpastes/adverse effects , Ultraviolet Rays/adverse effectsABSTRACT
Rosacea is a common and chronic inflammatory cutaneous disease with unknown etiology. The pathophysiology of rosacea is still poorly understood. Epidemiological studies indicate a genetic component, but a rosacea gene has not been detected yet. Recent molecular studies propose that an altered innate immune response is involved in the pathogenesis of the rosacea disease. Signs of rosacea are indicated by the presence of characteristic facial or ocular inflammation involving both the vascular and tissue stroma. A wide range of drug options is available for the treatment of rosacea, including several topical ones (metronidazole, antibiotics, azelaic acid, benzoyl peroxide, sulfacetamide/sulfur, retinoids) and oral ones (mainly tetracyclines, metronidazole, macrolides, isotretinoin). This review highlights the recent clinical and pathophysiological developments concerning rosacea.
Subject(s)
Anti-Infective Agents/therapeutic use , Dermatologic Agents/therapeutic use , Facial Dermatoses/diagnosis , Facial Dermatoses/therapy , Rosacea/diagnosis , Rosacea/therapy , Diagnosis, Differential , Facial Dermatoses/epidemiology , Facial Dermatoses/etiology , Humans , Intense Pulsed Light Therapy , Laser Therapy , Rhinophyma/pathology , Rhinophyma/therapy , Rosacea/epidemiology , Rosacea/etiologySubject(s)
Rosacea/etiology , Rosacea/pathology , Yoga , Adult , Diagnosis, Differential , Female , Forehead , Humans , Quality of Life/psychologyABSTRACT
Rosacea is a common, chronic, cutaneous disorder presenting with recurrent episodes of facial flushing, erythema, papules, pustules and telangiectasias. It is a multifactorial disease and its various clinical presentations probably represent the consequence of combined different triggers upon a specific background. Its management is largely based on long-established treatments empirically tailored to the specific presenting symptoms and no real breakthrough has occurred to date. However, recent insights into the still rather obscure pathophysiology of rosacea seem to open the way for etiologically oriented treatments. These may include, on the one side, the more effective application of traditional drugs, such as tetracyclines and metronidazole, to specifically selected patients or, on the other side, new therapeutic options, such as vitamin D receptor antagonists. It is to be remarked that the quality of most studies evaluating rosacea treatment is rather poor, mainly due to a lack of proper standardization. For a major breakthrough to occur in the management of rosacea, we need both a better understanding of its pathogenesis and the adherence of future clinical trials to clearly defined grading and inclusion criteria, which are crucial for investigators to correctly compare and interpret the results of their work.
Subject(s)
Rosacea/etiology , Rosacea/therapy , Adrenergic alpha-Agonists/therapeutic use , Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Antimicrobial Cationic Peptides/metabolism , Bacillus , Blind Loop Syndrome/complications , Blind Loop Syndrome/therapy , Cholecalciferol/therapeutic use , Gastrointestinal Tract/microbiology , Helicobacter Infections/complications , Helicobacter Infections/therapy , Helicobacter pylori , Humans , Mite Infestations/complications , Mite Infestations/therapy , Permethrin/therapeutic use , Phototherapy , Rosacea/physiopathology , Skin/metabolism , Skin/microbiology , CathelicidinsABSTRACT
Rosacea is a common chronic inflammatory disorder of the facial skin characterized by periods of exacerbation, remission and possible progression. The principle subtypes include erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea and ocular rosacea. Although the pathogenesis is unknown, rosacea is largely recognized as an inflammatory disorder. Individual subtypes are likely a result of different pathogenic factors and respond best to different therapeutic regimens. The non-pharmacologic approach to therapy is adequate skin care, trigger avoidance and photoprotection; in addition, there are several topical, herbal, systemic and light based therapies available. Standard Food and Drug Administration (FDA) approved treatments include topical sodium sulfacetamide, metronidazole, and azelaic acid. Anti-inflammatory dose doxycycline, a controlled-release 40 mg formulation offers a non-antibiotic, anti-inflammatory treatment option. Combination of azelaic acid or topical metronidazole with anti-inflammatory doxycycline appears to have a synergistic effect. Oral isotretinoin may be effective for phymatous rosacea and treatment resistant rosacea. Light based therapies with pulsed dye laser and intense pulsed light are effective in treatment of erythema and telangiectasias. As our knowledge of rosacea and its therapeutic options expand, a multifaceted approach to treatment is warranted.
Subject(s)
Dermatologic Agents/therapeutic use , Rosacea/therapy , Administration, Cutaneous , Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Combined Modality Therapy , Cosmetics/adverse effects , Dermatologic Agents/classification , Diet/adverse effects , Drug Therapy, Combination , Female , Humans , Lasers, Dye/therapeutic use , Low-Level Light Therapy , Male , Mite Infestations/complications , Phototherapy , Phytotherapy , Pregnancy , Pregnancy Complications/therapy , Randomized Controlled Trials as Topic , Rosacea/classification , Rosacea/epidemiology , Rosacea/etiology , Rosacea/microbiology , Rosacea/parasitology , Rosacea/prevention & control , Skin/blood supply , Skin/microbiology , Skin/parasitologyABSTRACT
Rosacea is a chronic, inflammatory skin disease which is mainly localized in the central region of the face. Papules and pustules appear on the erythematic ground. Rosacea is common in population. Four subtypes of rosacea (erythematoteleangiectatic rosacea, ETR; papulo - pustular rosacea, PPR; ocular rosacea and phymatous rosacea) are classified (according to current classification) and one variant rosacea (granulomatous rosacea, GR). It is considered that an attempt to determine of triggering factors of rosacea should be the first step to treatment. Then it should be tried to eliminate contact with them. The aim of this study was an analysis of triggering factors of rosacea. 43 women and 26 men treated in the Dermatology Outpatient's Clinic of Jagiellonian University School of Medicine in Cracow were enrolled in the study. All patients were asked which factors trigger skin changes according to them. Patients mentioned most often: stress (58 percent), sun exposure (56.5 per. cent), alcohol (33.3 percent), exercise (29 percent), drinking coffee (21.7 percent) and hot meals (20.3 percent). They regarded the sun as the most strongly aggravating factor of rosacea (29.2 percent). It seems, that elimination and reduction of contact with aggravating factors is still an undervalued aspect of rosacea's treatment. Patients' motivation for use of prevention seems to be also very important. Knowledge about aggravating factors of rosacea, coming directly from patients' observations, may help in more effective treatment.
Subject(s)
Health Knowledge, Attitudes, Practice , Rosacea/etiology , Rosacea/prevention & control , Adult , Alcohol Drinking , Coffee , Exercise , Feeding Behavior , Female , Humans , Male , Population Surveillance , Risk Factors , Rosacea/classification , Stress, Physiological/complications , SunlightABSTRACT
BACKGROUND: Patients with immunodeficiency are prone to infestation with Demodex folliculorum mites. Ultraviolet (UV) radiation can lead to immunosuppression and sebaceous gland hyperplasia. Although some cases of demodicidosis related to UV radiation exposure have been reported, no studies have been performed on the incidence of D. folliculorum and its clinical characteristics in patients receiving phototherapy. Objective To investigate the effects of phototherapy on the density of D. folliculorum infestation and its clinical characteristics. METHODS: This was a cross-sectional study. Forty-five patients receiving phototherapy and 43 age- and sex-matched healthy controls were enrolled to the study. The sociodemographic characteristics, occupational information, and skin types (2, 3, 4, or 5) of both patients and controls were carefully recorded. The dermatologic diseases requiring phototherapy, type and number of phototherapy treatments, and cumulative UV doses of all patients were noted. The clinical findings that may relate to demodicidosis were recorded. Standardized skin surface biopsies were taken from three anatomic regions (forehead, cheek, and nasal dorsum) and suspected lesions; five or more D. folliculorum mites per square centimeter of skin was defined as demodicidosis. RESULTS: Twelve (26.7%) patients received psoralen plus UV-A (PUVA) and 33 (73.3%) received narrow-band UV-B. Demodicidosis was detected in 13 (28.9%) patients and three (7%) controls. The difference in the demodicidosis rate between patients and controls was statistically significant (P = 0.01). In eight of the 13 patients (61.5%) with demodicidosis, clinical demodicidosis was present. Demodicidosis was present in seven of the 12 patients (58.3%) receiving PUVA and in six of the 33 patients (18.2%) receiving narrow-band UV-B. The difference in demodicidosis rates between patients receiving PUVA and those receiving narrow-band UV-B was statistically significant (P = 0.02). A statistically significant difference was also found between the mean D. folliculorum densities of patients and controls in all anatomic regions. CONCLUSION: Demodicidosis should be included in the differential diagnosis of facial eruptions in patients receiving phototherapy.
Subject(s)
Face/parasitology , Mite Infestations/etiology , Mites , Photochemotherapy/adverse effects , Phototherapy/adverse effects , Skin Diseases, Parasitic/etiology , Adolescent , Adult , Animals , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Mite Infestations/parasitology , Pityriasis/etiology , Pityriasis/parasitology , Psoriasis/therapy , Radiation Dosage , Rosacea/etiology , Rosacea/parasitology , Skin Diseases, Parasitic/parasitology , Statistics, Nonparametric , Vitiligo/therapyABSTRACT
Approximately 13 million individuals in the United Sates suffer from rosacea, a recurrent disease that may require long-term therapy. Topical and oral antibiotics have been used to treat rosacea; however, high-dose antibiotics or long-term, low-dose antibiotics commonly used for the treatment of rosacea flares or for rosacea maintenance therapy, respectively, can lead to the development of antibiotic-resistant organisms. The first oral medication approved by the U.S. Food and Drug Administration for the treatment of rosacea in the United States is Oracea (CollaGenex Pharmaceuticals Inc., Newtown, PA, USA). Oracea is a 40 mg capsule of doxycycline monohydrate, containing 30 mg immediate-release and 10 mg delayed-release doxycycline beads ("anti-inflammatory-dose doxycycline"). Anti-inflammatory-dose doxycycline is not an antibiotic and does not lead to the development of antibiotic-resistant organisms. Each capsule of anti-inflammatory-dose doxycycline contains a total of 40 mg of anhydrous doxycycline as 30 mg of immediate-release and 10 mg of delayed-release beads. In contrast to other oral therapies, anti-inflammatory-dose doxycycline is taken once daily, which may increase treatment compliance. The results of two phase III trials have been encouraging, leading to the recent release (summer 2006) of Oracea for the treatment of rosacea in the United States. Anti-inflammatory-dose doxycycline should not be used by individuals with known hypersensitivity to tetracyclines or increased photosensitivity, or by pregnant or nursing women (anti-inflammatory-dose doxycycline is a pregnancy category-D medication). The risk of permanent teeth discoloration and decreased bone growth rate make anti-inflammatory-dose doxycycline contraindicated in infants and children. However, when used appropriately in patients with rosacea, anti-inflammatory-dose doxycycline may help prolong the effectiveness and life span of our most precious antibiotics.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Doxycycline/therapeutic use , Drug Resistance , Rosacea/drug therapy , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Doxycycline/administration & dosage , Doxycycline/adverse effects , Female , Humans , Male , Patient Compliance , Rosacea/etiology , Rosacea/physiopathology , Skin/anatomy & histologyABSTRACT
Rosacea presents an enigma to patients and physicians alike. Although new insights and a plethora of therapies provide hope, the underlying etiology remains unknown. This assures a certain amount of frustration as available treatments temporize rather than cure the disease. This article examines the current state of knowledge regarding this fascinating entity.
Subject(s)
Complementary Therapies , Rosacea/classification , Rosacea/therapy , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/therapeutic use , Clinical Trials as Topic , Combined Modality Therapy , Dermatologic Agents/administration & dosage , Dermatologic Agents/therapeutic use , Drug Administration Routes , Humans , Rosacea/etiologyABSTRACT
Despite an incomplete understanding of the pathogenesis of rosacea, therapeutic modalities continue to expand. The principal subtypes of rosacea include erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, and ocular rosacea. These phenotypic expressions are probably caused by divergent pathogenic factors and consequently respond to different therapeutic regimens. A subtype-directed approach to therapy is discussed in part II of this review. We provide an overview of the available topical, oral, laser, and light therapies in the context of these cutaneous subtypes, review the evidence that supports their use, and outline their therapeutic approach. Suggestions for future areas of study also are provided. Learning objective At the completion of this learning activity, participants should be familiar with the subtype-directed approach to therapy for rosacea including available topical, oral, laser, and light therapies.